Study Results from T. Catic et al Provide New Insights into Pain (Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in…

Drug Week

Study Results from T. Catic et al Provide New Insights into Pain (Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin)

By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Neurologic Manifestations - Pain have been presented. According to news reporting out of Sarajevo, Bosnia and Herzegovina, by NewsRx editors, research stated, "Neuropathic pain resulting from injury to the nervous system. Up to 7% to 8% of the European population is affected."

Our news journalists obtained a quote from the research, "A number of different treatments for neuropathic pain have been studied including antiepileptic. Pregabalin and gabapentin are often considered first-line treatments. Pregabalin provides equivalent efficacy to gabapentin, showing greater potency at much lower doses and is considered as cost-effective intervention. In Federation of Bosnia and Herzegovina (FB&H), gabapentin is fully reimbursed, while pregabalin is enlisted on list B with copayment. To develop simple budget impact (BI) model and assess BI of introducing pregabalin into full reimbursement in FB&H. Budget impact model was developed using Microsoft Excel 2010. Local epidemiology data and data on drug consumption from government reports in 2016 were used. Two scenarios with three-year time horizon have been developed: 1) without and 2) with pregabalin reimbursed at the same level as gabapentin. Two developed scenarios have been compared from health insurance fund (HIF) perspective. In scenario 1 consider both drugs fully reimbursement and without patient switch among alternatives the total cost would be increased for 780,025 KM; 852,027 KM and 943,830 KM over a 3-year period. In scenario 2 considering both drugs fully reimbursed but with patient switch topregabalin total annual cost would be increased for 732,241 KM; 742,395 KM and 751,761 KM. Comparing scenario 1 and 2 it is found that scenario 2 is more favorable from HIF perspective."

According to the news editors, the research concluded: "Implementation of pharmacoeconomic principles in reimbursement decisions in Bosnia and Herzegovina would improve access to medicines and contribute rationale resource consumption."

For more information on this research see: Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin. Materia Socio-medica, 2018;30(2):89-94 (see also Neurologic Manifestations - Pain).

Our news journalists report that additional information may be obtained by contacting T. Catic, Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. Additional authors for this research include R. Jusufovic and V. Tabakovic.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.5455/msm.2018.30.89-94. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Anticonvulsants, Antiepileptics, Pharmaceuticals, Sarajevo, Epidemiology, Neuropathic Pain, Gabapentin Therapy, Pregabalin Therapy, Drugs and Therapies, Health and Medicine, Bosnia and Herzegovina, Neurologic Manifestations, Central Nervous System Agents, Gamma aminobutyric Acid Analogs.